
    
      This study will be an open label study of secukinumab for the treatment of nail psoriasis.
      Secukinumab is an FDA-approved treatment for psoriasis. This is a single arm trial - all
      patients will receive the study drug. We will examine time to response and different methods
      of defining nail disease response.
    
  